Urethral bulking agents are commonly used for the management of stress urinary incontinence (SUI). Little long-term data exist for these agents, with few reports of migration or urethral erosion. We describe a unique case of a woman who received a midurethral sling 3 years after receiving an injection of the urethral bulking agent, polydimethylsiloxane, because of persistent SUI. Her subsequent recurrent urinary tract infections led to the identification of a bladder neck erosion of the urethral bulking agent with a concomitant calcification. When irritative voiding symptoms are experienced in patients who have received urethral bulking agents, erosion must be considered. Furthermore, little is known regarding the definitive management of SUI in patients that have previously received an injection of a urethral bulking agent.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383412 | PMC |
http://dx.doi.org/10.1089/cren.2019.0007 | DOI Listing |
Int Urogynecol J
December 2024
Clinique Sainte Barbe, Groupe Hospitalier Saint Vincent, Strasbourg, France.
Introduction And Hypothesis: Various treatment options are currently available for the management of stress urinary incontinence (SUI). This study was aimed at determining the effectiveness and safety profile of Bulkamid, and identify predictive factors of clinical success.
Methods: This retrospective study conducted in two French urogynecology university centers between September 2019 and December 2023 included all patients with urinary incontinence who received Bulkamid.
Ugeskr Laeger
November 2024
Urologisk Afdeling L, Odense Universitetshospital.
Stress urinary incontinence can be treated surgically with bulking agents. This is a report of two cases: I. A 42-year-old woman had successful bulking in 2007, in 2023 there was a urological assessment due to an incidental cystic process near the urethra, and bulking agents were resected leading to severe incontinence due to sphincter insufficiency.
View Article and Find Full Text PDFUrology
November 2024
Department of Urology, University of Rennes, Rennes, France.
Objective: To report our experience of outpatient periurethral injections of Bulkamid under local anesthesia in the office in female patients for stress urinary incontinence (SUI). Polyacrylamide hydrogel (Bulkamid) is a relatively recent bulking agent which may have a better safety profile than previous generations.
Methods: The data of all women who underwent outpatient periurethral Bulkamid injections under local anesthesia in the office at a single academic center were collected prospectively between November 2019 and August 2023.
Urology
November 2024
Department of Urology, Tenon Academic Hospital, Assistance-Publique - Hôpitaux de Paris, Sorbonne University, Paris, France.
Int Urogynecol J
December 2024
1st Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Periferiaki Odos Thessalonikis, Nea Efkarpia, 56403, Thessaloniki, Greece.
Introduction And Hypothesis: Various instruments are used to evaluate the severity of stress urinary incontinence (SUI) in clinical trials for SUI surgery. We conducted a scoping review with the primary aim of investigating the use of such instruments.
Methods: A comprehensive search in PubMed/MEDLINE, Cochrane Library, ClinicalTrials.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!